Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/02/21
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/02/21
Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/27/21
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative ActionGlobeNewsWire • 08/27/21
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/05/21
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/30/21
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More24/7 Wall Street • 06/15/21
Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/17/21
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/07/21
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/29/21
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/10/21
Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?24/7 Wall Street • 01/19/21